Last quarter (Q3 2023), Quoin Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Quoin Pharmaceuticals's net income was $-1.93M. See Quoin Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	-	-	$ -20.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	$ -20.00K
Operating Expense	$ 7.16M	$ -9.26M	$ -6.06M	$ -1.67M	$ -22.33M	$ -29.25M
Operating Income	$ -7.16M	$ -9.26M	$ -6.06M	$ -1.67M	$ -22.33M	$ -29.27M
Net Non Operating Interest Income Expense	$ 536.07K	$ -541.10K	$ -1.37M	$ -47.02K	$ 6.99M	$ 9.15M
Other Income Expense	$ 11.93K	$ -417.31K	$ 14.03M	$ -378.33K	-	$ -20.00K
Pretax Income	$ -6.64M	$ -9.38M	$ -21.46M	$ -2.10M	$ -15.34M	$ -20.11M
Tax Provision	-	$ -388.00K	-	-	$ -1.47M	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -6.64M	$ -9.45M	$ -21.46M	$ -2.10M	$ -16.81M	$ -20.11M
Basic EPS	$ -4.42	$ -3.90	$ -0.01	$ -8.75	$ 1.00	$ 0.16
Diluted EPS	$ -4.42	$ -3.90	$ -0.01	$ -8.75	-	-
Basic Average Shares	$ 9.62M	$ 2.42M	$ 1.58B	$ 96.12M	$ 17.01M	$ 129.43M
Diluted Average Shares	$ 9.62M	$ 2.42M	$ 1.58B	$ 96.12M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 7.16M	$ -9.26M	$ -6.06M	$ -1.67M	$ -22.33M	$ -29.25M
Net Income From Continuing And Discontinued Operation	$ -6.64M	$ -9.38M	$ -21.46M	$ -2.10M	$ -16.81M	$ -20.11M
Normalized Income	$ -3.19M	-	-	-	-	-
Interest Expense	-	-	-	-	-	-
EBIT	$ -6.64M	$ -9.38M	$ -20.49M	$ -2.05M	$ -22.33M	$ -29.27M
EBITDA	$ -6.56M	$ -9.28M	$ -20.39M	-	-	-

Currency in USD

Quoin Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing